Evidence map›Paper›PMID 36430928›Full record

ArticleInternational journal of molecular sciences2022

Małgorzata Sobocińska, Jakub Fichna, Artur Giełdoń, Piotr Skowron, Elżbieta Kamysz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Małgorzata SobocińskaLaboratory of Chemistry of Biological Macromolecules, Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, 80-308 Gdansk, Poland.
Jakub FichnaDepartment of Biochemistry, Faculty of Medicine, Medical University of Lodz, 92-215 Lodz, Poland.ORCID 0000-0002-8443-4417
Artur GiełdońLaboratory of Simulation of Polymers, Department of Theoretical Chemistry, Faculty of Chemistry, University of Gdansk, 80-308 Gdansk, Poland.ORCID 0000-0003-0415-9214
Piotr SkowronLaboratory of Bionanotechnology, Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, 80-308 Gdansk, Poland.ORCID 0000-0003-1345-3271
Elżbieta KamyszLaboratory of Chemistry of Biological Macromolecules, Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, 80-308 Gdansk, Poland.ORCID 0000-0002-9741-4562
University of Gdańsk · PLMedical University of Lodz · PL

Funding

Medical University of Lodz 503/1-156-04/503-11-001-19-00 to JFUniversity of Gdańsk 531-T040-D838-22 to EK
6 · The paper itself

Abstract

Pharmacotherapy for inflammatory bowel disease (IBD) is difficult, and some patients do not respond to currently available treatments. Therefore, the discovery of novel anti-IBD agents is imperative. Our aim was the synthesis of lipidated analogs of sialorphin and the in vitro characterization of their effect on the degradation of Met-enkephalin by neutral endopeptidase (NEP). We also investigated in vivo whether the most active inhibitor (peptide

Indexed as

ColitisNeprilysinAnimalsEnkephalinsInflammationMicePeptidesEnkephalinsNeprilysinPeptidessialorphinenkephalinsmolecular modellingneutral endopeptidasepeptides synthesissialorphinstructure–activity relationship

Identifiers

PMID36430928
PMCPMC9695599
OpenAlexW4309738103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.